Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

“Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show potential to ...

Dan Atkins, vice president of digital innovation and insight at Shionogi Europe ... for COVID-19 and respiratory syncytial virus (RSV). Join the conversation, on Tuesday 28th January @ 10 am ...

Included among these is RSV - high levels of which were found in North Carolina's wastewater. Here's what to know about RSV, its presence in N.C. and how to recognize and prevent illness.

COVID-19 and flu activity is increasing in most parts of the country and RSV activity remains very high, especially in young children. Respiratory illness activity in Florida is very high ...

The report also showed emergency department visits for RSV — a common virus that typically causes mild, cold-like symptoms — are at "very high" levels in the state. ER visits for COVID-19 are ...

Pregnant women across Australia will be offered a free vaccine to protect their babies against respiratory syncytial virus (RSV) from next month. The government's $174.5 million investment will ...

But there's a fourth "bug" the public should be aware of: respiratory syncytial virus. RSV causes cold-like symptoms and affects the breathing passages and lungs. Wastewater levels of RSV are ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...